<DOC>
	<DOCNO>NCT01023880</DOCNO>
	<brief_summary>The primary objective part 1 study determine maximum tolerate dose ( MTD ) CEP-18770 patient relapse refractory multiple myeloma . The primary objective part 2 evaluate antitumor activity CEP-18770 patient treat MTD .</brief_summary>
	<brief_title>Study Determine Maximum Tolerated Dose Evaluate Efficacy Safety CEP-18770 ( Delanzomib ) Patients With Relapsed Multiple Myeloma Refractory Most Recent Therapy</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Delanzomib</mesh_term>
	<criteria>Key The patient : relapsed multiple myeloma progress follow therapy include bortezomib IMiD ( thalidomide lenalidomide ) either alone combination . multiple myeloma , refractory recent therapy ( bortezomib IMiD , chemotherapy ) , patient tolerate discontinue recent therapy multiple myeloma recover toxic effect . measurable disease define 1 following : serum Mprotein ≥0.5 g/dL urine Mprotein ≥200 mg/24 hour life expectancy 3 month . ECOG performance status 0 , 1 , 2. adequate hepatic organ function . absolute neutrophil count ( ANC ) , hemoglobin level , platelet count within protocolspecific range . independent granulocytecolony stimulate factor ( GCSF ) granulocyte macrophagecolony stimulate factor ( GMCSF ) support 1 week . independent platelet transfusion 1 week . receive , may receive , allogeneic and/or autologous transplant . creatinine clearance 30 mL/minute measure calculate base CockcroftGault method . patient female childbearing potential ( surgically sterile 1 year postmenopausal ) : must use medically accept method contraception ( include abstinence ) must agree continue use method duration study 3 month participation study . patient male : surgically sterile , sexually active , currently use effective barrier method contraception , agree continue use method duration study 3 month last administration study drug . Key The patient : nonmeasurable multiple myeloma . receive glucocorticoid therapy ( prednisone &gt; 10 mg/day orally equivalent ) within last 2 week prior first dose study drug . POEMS syndrome ( polyneuropathy , organomegaly , endocrinopathy , monoclonal gammopathy monoclonal proliferative disorder , skin change ) . plasma cell leukemia . receive chemotherapy approve anticancer therapeutic within 2 week , within 5 drug halflives ( t1/2 ) , investigative anticancer therapeutic within 4 week , within 5 drug halflives ( t1/2 ) , first dose study drug , whichever time great . receive radiation therapy immunotherapy 4 week prior , localize radiation therapy within 1 week prior , first dose study drug . receive prior treatment CEP18770 . use medication know potent inducer CYP2E1 , CYP2D6 CYP3A4/5 within 4 week prior first dose study drug . use medication know potent inhibitor CYP2E1 , CYP2D6 CYP3A4/5 within 2 week prior first dose study drug . major surgery within 3 week first dose study drug . congestive heart failure symptomatic ischemia , conduction abnormality uncontrolled conventional intervention , myocardial infarction within last 6 month . acute infection require systemic antibiotic , antiviral agent , antifungal agent within 2 week first dose study drug . know suspected human immunodeficiency virus ( HIV ) infection basis medical history . nonhematologic malignancy within past 3 year except follow : adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix breast , prostate cancer ( Gleason grade &lt; 6 prostate specific antigen ( PSA ) level within normal range ) . myelodysplastic myeloproliferative syndrome . significant neuropathy . pregnant lactate woman . Any woman become pregnant study withdrawn study . know central nervous system involvement . serious psychiatric medical condition could interfere treatment study procedure , place patient unacceptable risk , hind interpretation study data . know hypersensitivity mannitol hydroxypropyl betadex .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>